Overview

We are focused on leveraging core expertise in drug discovery and development and kinase inhibition to develop novel, small molecule therapies to help people impacted by under served immuno-inflammatory conditions. Our team of experienced and accomplished kinome experts use the proprietary KINect® technology platform to generate clinical candidates for difficult to drug kinases with novel approaches. The ability to systemically and efficiently attach human kinases with adenosine triphosphate (ATP) site cysteines (the human cysteinome) differentiates Aclaris from competitors.

Aclaris operates Confluence Discovery Technologies, Inc., a full-service drug discovery and early development contract research organization, as an indirect, wholly-owned subsidiary. Confluence serves as a research partner for pharma and biotech companies across therapeutic areas and gene families. Confluence’s expertise includes cell and molecular biology, biochemistry, enzymology, biomarker development, immunology and inflammation, in vivo efficacy models, bioanalytical, computational and medicinal chemistry. To learn more, visit www.confluencediscovery.com.

Aclaris COVID-19 Response

Our People and Offices

What is Aclaris doing to protect against the spread of COVID-19 in our offices?

At Aclaris, we take the health and safety of our employees, their families, and our local communities very seriously and we are actively responding to the COVID-19 pandemic.

We have a COVID-19 Task Force dedicated to preparing for and protecting against the transmission of COVID-19 in our offices and in the local community, while ensuring the critical work required to develop immuno-inflammatory medicines for patients with debilitating conditions continues. In this effort, we have implemented several measures, such as:

  • Required employees to work remotely and restricted access to our offices
  • Restricted laboratory access to personnel who needed to conduct essential business continuity activities on a staggered work schedule
  • Implemented social distancing and additional cleaning throughout our offices to help protect employees who continue to work in our offices
  • Suspended all visitor access
  • Replaced in-person interactions with virtual meetings
  • Suspended all business travel
  • Closely monitored appropriate health authorities and fully complied with all Centers for Disease Control and Prevention (CDC) and applicable state and local government regulations and protocols

Research and Development

The global outbreak of COVID-19 continues to rapidly evolve and has caused and may continue to cause Aclaris to experience disruptions that could impact the timing of its regulatory and research and development activities. Click here to learn more.